Should a molecular lab build or buy a payer-policy tracking system?

It depends on scale and change velocity, not on a universal answer. Building gives you full control but transfers the permanent cost of maintenance onto your team, because the policies never stop changing. Buying gives you speed and coverage but requires careful evaluation of fit: which sources are tracked, how fast changes are detected, and whether the output is just an alert or an actionable, structured rule your systems can use. The deciding factor is usually whether payer-policy maintenance is a core competency you want to own or a commodity you want handled.

How often do the payer policies that affect molecular testing change?

Continuously, and across many sources at once: Medicare NCDs and LCDs, MolDX requirements, and dozens of commercial medical policies. Recent examples include Medicare's NGS NCD changes in 2018 and 2020, the MolDX DEX Z-Code becoming a hard claim-rejection gate on May 1, 2025, UnitedHealthcare's 2024 commercial Z-Code requirement, and the CMS-0057-F prior-authorization timelines that took effect in 2026. No single one is dramatic; the burden is the steady accumulation.

What does it cost to track payer policy in-house?

The dominant cost is skilled staff time rather than software. Someone has to monitor each source, read every relevant update, decide which tests and indications it affects, and propagate the change into billing rules and workflows, repeatedly, as policies keep moving. The cost is real but largely invisible because it is buried in headcount and in the denials that slip through when a change is missed.

What is the risk of getting payer-policy tracking wrong?

Denials, and they are measurable. A 2025 JAMA Network Open study found 23.3% of Medicare cancer-NGS claims were denied, rising to 27.4% after the 2020 coverage expansion, with a median denied charge of $3,800. Most molecular denials are operational, meaning they trace back to a claim that did not match a current rule, which is exactly what stale policy tracking produces.

Build vs. Buy: Keeping Payer Policy Current for a Molecular Lab

Every molecular lab already has a payer-policy tracking system. It might be a senior biller who keeps the important changes in her head, a shared spreadsheet someone updates when they remember, a billing vendor whose rules you mostly trust, or a piece of software. The question is almost never whether to track payer policy. It is whether the way you track it now can keep pace with how fast it changes, and whether building a better version is smarter than buying one.

This article is meant to make that decision clearly, without pretending the answer is the same for every lab.

Disclaimer: This is educational, not legal, financial, or procurement advice. The right approach depends on your organization's specifics, and vendor capabilities change over time. Evaluate any solution against your own requirements and consult qualified professionals before making a buying or building decision. Use this information at your own risk.

First, be honest about what the job actually is

"Tracking payer policy" sounds like a monitoring task. It is really four tasks stacked on top of each other, and most build-versus-buy conversations go wrong because they only price the first one.

The first task is detection: noticing that something changed, across Medicare National and Local Coverage Determinations, MolDX requirements, and the medical policies of every commercial payer you bill. The second is interpretation: reading the change and understanding what it actually requires. The third is translation: turning that requirement into the specific rule that governs a given test, CPT code, indication, diagnosis, or documentation scenario. The fourth is propagation: getting that rule into the places where it has to act, your billing system, your work queues, your prior-authorization process, your staff's daily decisions, before a claim goes out under the old assumptions.

A spreadsheet handles detection, badly. It does nothing for the other three. When people say payer-policy tracking is hard, what they usually mean is that the last three tasks are invisible, unglamorous, and never finished, because the policies never stop moving.

The change never stops, and that is the whole point

The case for taking this seriously is not theoretical. Look at just the last two years of changes a molecular lab had to absorb:

Medicare's NGS coverage determination (NCD 90.2) shifted in 2018 and again in 2020, each time adding criteria that a claim must satisfy.
The MolDX program turned the DEX Z-Code into a hard gate: as of May 1, 2025, MolDX claims submitted without the Z-Code in the correct claim field deny as unprocessable, with no clinical review at all (per Noridian guidance).
UnitedHealthcare extended a DEX Z-Code requirement to its commercial molecular claims, announced for April 1, 2024 and then delayed to June 1, 2024.
The federal prior-authorization rule (CMS-0057-F) introduced new payer decision timelines effective January 1, 2026, with API requirements following in 2027.

None of these was front-page news inside a lab. Each one quietly changed the conditions a clean claim must meet, and each one created a fresh denial pattern for any lab that did not catch it in time. That is the real shape of the work: not a few big events you can plan around, but a constant drip you have to stay ahead of. Whatever you build or buy has to be built for the drip, not the headline.

The case for building

Building your own payer-policy capability has genuine advantages, and they are worth stating plainly so the decision is fair.

You get control. The rules are yours, shaped exactly to your test menu, your payer mix, and your interpretations. You get institutional knowledge: the analyst who has tracked a payer for three years understands its quirks in ways no generic tool encodes. And you avoid a vendor dependency for something central to your revenue.

The cost of building is not the initial setup. It is the maintenance, and it is permanent. Detection, interpretation, translation, and propagation are not a project you finish; they are a process you staff forever, because the policies keep changing. The expense is mostly skilled labor, and it is easy to underestimate because it hides inside headcount and inside the denials that leak through whenever a change is missed during a vacation, a turnover, or a busy quarter. Building is the right call when payer-policy operations is a competency you want to own and resource as a permanent function, not a side duty bolted onto a billing team that already has a day job.

The case for buying

Buying turns a permanent internal process into someone else's permanent process. The advantages are speed and breadth: a dedicated platform tracks far more sources, far more continuously, than most labs can justify staffing for, and it spreads that cost across many customers.

But "buy" is not one thing, and this is where labs get the decision wrong. The tools in this space differ enormously in what they actually deliver, and the differences map directly onto the four tasks above:

Some tools stop at detection and alerting, they tell you a policy changed and leave interpretation, translation, and propagation to you. Useful, but you still own three of the four jobs.
Some are oriented toward pharmaceutical market access rather than the operational reality of a diagnostics lab, so the data is real but framed for a different buyer.
Some deliver structured, usable rules rather than just notifications, which is the difference between knowing a policy moved and having the new requirement actually applied to the right test and indication.
Some expose that rule layer through an API or programmatic interface so it can flow into your own systems, billing, work queues, and even AI agents, instead of living in a dashboard a human has to check.

When you evaluate a "buy" option, those are the axes that matter: which sources it covers, how quickly it detects change, and how far down the chain it carries the work. A tool that only alerts you has handed back the hard part. A tool that delivers current, structured rules you can act on, ideally programmatically, has actually absorbed the burden.

The decision, distilled

Strip away the noise and the choice comes down to a few honest questions.

How many payers and tests do you have to keep current, and how often do those policies change? The higher the volume and velocity, the worse spreadsheets and tribal knowledge scale, and the stronger the case for a dedicated capability, built or bought.

Is payer-policy operations a core competency you want to own and staff permanently, or a commodity you want handled so your people can focus elsewhere? Be honest about whether you will actually fund the in-house version through turnover and busy seasons, or whether it will quietly degrade.

And if you buy, does the tool carry the work all the way to an actionable, current rule, or does it just tell you something changed? The whole value is in how much of detection, interpretation, translation, and propagation it genuinely takes off your plate.

What "good" looks like, and where this points

The reason this decision matters is that the cost of getting it wrong is measurable. A 2025 JAMA Network Open study found that 23.3% of Medicare cancer-NGS claims were denied, climbing to 27.4% after coverage expanded in 2020, with a median denied charge of $3,800. Most molecular denials are operational, which is another way of saying they are produced by claims that did not match a current rule. Stale policy tracking is not a tidy inconvenience; it is the upstream source of a meaningful share of your denial rate.

The strongest position a lab can be in is to treat payer policy as live data, detected at the source, translated into the specific rules that govern each test and indication, kept current automatically, and delivered into the systems and workflows where it has to act, including through an API or MCP so your own tools and agents can use it directly. That is the bar to hold any option against, build or buy. It is also, candidly, the standard Converus was designed to meet: a maintained rule layer over payer policy, contracts, fee schedules, and mandates, usable across your team, your systems, and your AI workflows. Whether you build that capability or buy it, the goal is the same, your claims should reflect today's rules, not last year's.

Sources

Claim Denials for Cancer-Related Next-Generation Sequencing in Medicare — JAMA Network Open, April 18, 2025 (doi:10.1001/jamanetworkopen.2025.5785; PubMed 40249617)
Proper Submission of DEX Z-Code for Molecular Diagnostic Services (MolDX) Claims — Noridian Healthcare Solutions (effective May 1, 2025)
Make Sure Molecular Tests Have a Z-Code Assigned — UnitedHealthcare (commercial Z-Code requirement, 2024)
CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) — Centers for Medicare & Medicaid Services
National Coverage Determination (NCD 90.2): Next Generation Sequencing — Centers for Medicare & Medicaid Services